Simris Alg (SIMRIS-B.ST) Stock Analysis & AI Equity Report
Simris Alg (SIMRIS-B.ST) overview
Simris Alg (SIMRIS-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Simris Alg reported revenue of SEK 1.6m and operating profit of SEK -31.3m; the year-end share price was 0.04 SEK and market capitalisation was SEK 36.0m. Simris Alg is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Simris Alg's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Simris Alg
Simris Alg AB is a Swedish biotechnology company that develops natural compounds from microalgae and cyanobacteria for use in biopharmaceuticals, dietary supplements, and cosmetics. The group has built its business around proprietary discovery, strain libraries, and bioconjugation methods, with a current focus on next-generation antibody-drug conjugate payloads and related research partnerships.
Generate the Simris Alg report
Simris Alg is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Simris Alg and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.